Free Trial

Cellectar Biosciences (CLRB) Competitors

Cellectar Biosciences logo
$2.06
+0.03 (+1.48%)
(As of 09:52 AM ET)

CLRB vs. OCUP, MLND, BMEA, CMPS, ITOS, JSPR, TSHA, RZLT, PRQR, and ACB

Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Ocuphire Pharma (OCUP), Millendo Therapeutics (MLND), Biomea Fusion (BMEA), COMPASS Pathways (CMPS), iTeos Therapeutics (ITOS), Jasper Therapeutics (JSPR), Taysha Gene Therapies (TSHA), Rezolute (RZLT), ProQR Therapeutics (PRQR), and Aurora Cannabis (ACB). These companies are all part of the "medical" sector.

Cellectar Biosciences vs.

Ocuphire Pharma (NASDAQ:OCUP) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

15.0% of Ocuphire Pharma shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 8.7% of Ocuphire Pharma shares are held by insiders. Comparatively, 3.7% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cellectar Biosciences has a net margin of 0.00% compared to Ocuphire Pharma's net margin of -85.75%. Cellectar Biosciences' return on equity of 0.00% beat Ocuphire Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Ocuphire Pharma-85.75% -30.19% -27.55%
Cellectar Biosciences N/A N/A -176.62%

Ocuphire Pharma has higher revenue and earnings than Cellectar Biosciences. Ocuphire Pharma is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocuphire Pharma$16.45M1.84-$9.99M-$0.49-2.39
Cellectar BiosciencesN/AN/A-$37.98M-$2.53-0.80

In the previous week, Cellectar Biosciences had 4 more articles in the media than Ocuphire Pharma. MarketBeat recorded 4 mentions for Cellectar Biosciences and 0 mentions for Ocuphire Pharma. Ocuphire Pharma's average media sentiment score of 0.00 equaled Cellectar Biosciences'average media sentiment score.

Company Overall Sentiment
Ocuphire Pharma Neutral
Cellectar Biosciences Neutral

Ocuphire Pharma currently has a consensus target price of $16.00, indicating a potential upside of 1,267.52%. Cellectar Biosciences has a consensus target price of $21.00, indicating a potential upside of 934.48%. Given Ocuphire Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ocuphire Pharma is more favorable than Cellectar Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocuphire Pharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
Cellectar Biosciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cellectar Biosciences received 204 more outperform votes than Ocuphire Pharma when rated by MarketBeat users. However, 69.81% of users gave Ocuphire Pharma an outperform vote while only 55.92% of users gave Cellectar Biosciences an outperform vote.

CompanyUnderperformOutperform
Ocuphire PharmaOutperform Votes
37
69.81%
Underperform Votes
16
30.19%
Cellectar BiosciencesOutperform Votes
241
55.92%
Underperform Votes
190
44.08%

Ocuphire Pharma has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.

Summary

Ocuphire Pharma beats Cellectar Biosciences on 10 of the 17 factors compared between the two stocks.

Get Cellectar Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLRB vs. The Competition

MetricCellectar BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$82.35M$7.03B$5.33B$8.60B
Dividend YieldN/A7.98%5.14%4.03%
P/E Ratio-0.8012.10129.9316.91
Price / SalesN/A406.041,691.4398.30
Price / CashN/A22.4935.4031.50
Price / Book-5.645.784.824.68
Net Income-$37.98M$154.13M$118.56M$223.96M
7 Day Performance-0.98%-0.41%1.44%0.87%
1 Month Performance-7.73%15.39%7.42%4.74%
1 Year Performance-18.47%39.58%37.24%29.14%

Cellectar Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLRB
Cellectar Biosciences
1.8987 of 5 stars
$2.06
+1.5%
$21.00
+919.4%
-23.4%$83.57MN/A-0.8110Upcoming Earnings
News Coverage
OCUP
Ocuphire Pharma
2.1528 of 5 stars
N/A$16.00
+∞
-57.3%$30.33M$16.45M-2.3914Upcoming Earnings
High Trading Volume
MLND
Millendo Therapeutics
N/A$0.91
-1.1%
N/A-74.4%$17.32MN/A0.0012
BMEA
Biomea Fusion
3.8007 of 5 stars
$9.04
-3.5%
$30.50
+237.4%
-11.7%$327.61MN/A-2.2550Analyst Revision
Gap Up
CMPS
COMPASS Pathways
2.263 of 5 stars
$4.75
-0.2%
$47.40
+897.9%
-29.5%$324.85MN/A-2.06120Earnings Report
High Trading Volume
ITOS
iTeos Therapeutics
2.322 of 5 stars
$8.81
+4.3%
$30.50
+246.2%
-10.8%$321.74M$12.60M-2.9490Positive News
JSPR
Jasper Therapeutics
2.9625 of 5 stars
$21.27
+0.4%
$74.86
+251.9%
+215.4%$321.18MN/A-4.1720Gap Up
TSHA
Taysha Gene Therapies
1.564 of 5 stars
$1.53
-9.5%
$6.38
+316.7%
-48.8%$313.56M$15.45M-7.65180Upcoming Earnings
News Coverage
Gap Up
High Trading Volume
RZLT
Rezolute
3.9334 of 5 stars
$5.50
+0.4%
$11.57
+110.4%
+444.0%$307.62MN/A-4.1440Upcoming Earnings
Analyst Forecast
News Coverage
PRQR
ProQR Therapeutics
3.0276 of 5 stars
$3.73
+6.6%
$5.88
+57.5%
+195.9%$304.67M$7.05M-12.86180Gap Up
ACB
Aurora Cannabis
0.7019 of 5 stars
$5.54
+2.2%
N/A+24.7%$303.83M$278.98M-7.911,073News Coverage
Gap Down

Related Companies and Tools


This page (NASDAQ:CLRB) was last updated on 11/6/2024 by MarketBeat.com Staff
From Our Partners